INT265802

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.04
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 1.01
Pain Relevance 0.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (KLKB1) extracellular space (KLKB1) extracellular region (KLKB1)
plasma membrane (KLKB1)
Anatomy Link Frequency
plasma 9
KLKB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 17 98.00 Very High Very High Very High
metalloproteinase 24 97.72 Very High Very High Very High
antagonist 28 87.28 High High
B1 receptor 2 82.88 Quite High
Pain 4 76.76 Quite High
Restless leg syndrome 8 69.60 Quite High
b2 receptor 8 67.04 Quite High
addiction 24 5.00 Very Low Very Low Very Low
ischemia 16 5.00 Very Low Very Low Very Low
Central nervous system 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Peripheral Arterial Disease 144 99.24 Very High Very High Very High
Edema 51 79.20 Quite High
Hereditary Angioedema 91 78.24 Quite High
Pain 4 76.76 Quite High
Atherosclerosis 32 69.60 Quite High
Injury 10 65.20 Quite High
Pressure And Volume Under Development 16 58.32 Quite High
Eclampsia 24 53.64 Quite High
Vasculitis 8 52.60 Quite High
Increased Venous Pressure Under Development 16 45.04 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Steady-state effects of plasma clearance rates (kCL)
Regulation (effects) of plasma in plasma
1) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
As lymph flow directly transfers protein mass from the interstitial space into the blood, concentrations of VEGF and sVEGFR1 in muscle interstitia and in plasma could be sensitive to the muscle activity-dependent changes in lymph flow rates.
Regulation (sensitive) of plasma in plasma
2) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.25 Pain Relevance 0.07
Like strategies targeting plasma kallikrein, inhibition of factor XII activity might prevent bradykinin generation [80].
Regulation (targeting) of plasma kallikrein in plasma associated with bradykinin
3) Confidence 0.03 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.49 Pain Relevance 0.43
Receptor densities and ratios affected plasma and interstitial concentrations of VEGF and sVEGFR1, as well as surface-bound VEGFR occupancy
Regulation (affected) of plasma in plasma
4) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
The significance here is that the physiological variation in transport rates offers a case example where the common circulating angiogenic markers become unreliable, i.e., apparent changes in free VEGF or sVEGFR1 levels in the plasma do not correlate with changes in the actual angiogenic signaling potential in the tissues.
Regulation (changes) of plasma in plasma
5) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Here in this study, we have chosen to target the plasma concentrations of [V]pl?
Regulation (target) of plasma in plasma
6) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
A dynamic simulation of the diurnal changes of kL over a combination of “bed-rest days” and “active days”, as illustrated in Fig. 9C, suggested that physiological variation of kL over the course of a day can still account for significant variation in plasma concentrations of VEGF and sVEGFR1.
Regulation (concentrations) of plasma in plasma
7) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
We further showed that NRP1-dependent internalization of sVEGFR1 can be a major regulator of free sVEGFR1 levels in both interstitia and plasma, both directly (e.g., varying NRP1 densities) and indirectly (e.g., R2/R1 ratio and VEGF-VEGFR1 binding alter the availability of uncoupled NRP1s) (Fig. 5A, 6B).
Regulation (regulator) of plasma in plasma
8) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Abnormal plasma levels of MMPs in PAD [148], [149] may suggest a role for proteolytic degradation or release of VEGF165 in causing pathological bioavailabilities of VEGF.
Regulation (Abnormal) of plasma in plasma associated with peripheral arterial disease
9) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.27 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox